The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For 2025, competition and supply constraints are areas to watch.

Junk food companies are starting to get nervous over how many Americans use GLP-1 medications to lose weight. Washington Post ...

The holidays can be a difficult time for those with a history of eating disorders, and having someone comment on their body – ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

After about 10 months of being on Ozempic and working my way up to a 1-mg dose, I lost 40 pounds effortlessly. Sugar cravings ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

After about 10 months of being on Ozempic and working my way up to a 1-mg dose, I lost 40 pounds effortlessly. Sugar cravings disappeared as if by magic. I then noticed myself drifting backward and ...

Wegovy and Ozempic are the exact same drug: semaglutide. They are dosed slightly differently and marketed for different ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.